Mefloquine during the study. Mefloquine was the first Public-Private Venture (PPV) between the US Department of Defense and a pharmaceutical company. WRAIR transferred all its phase I and phase II clinical trial data to Hoffman LaRoche and Smith Kline. FDA approval as a treatment for malaria was swift. Most notably, phase III safety and tolerability trials were skipped. The drug was first approved and sold on a commercial basis in Switzerland in 1985. However, mefloquine was not approved by the FDA for prophylactic use until 1989. This approval was based primarily on compliance, while safety and tolerability were overlooked. Because of
International Association for the Treatment of Sexual Offenders medical treatments, or other psychical interventions. Probation supervision and residential placement are not considered treatment for this specific age group. However, they are still important aspects of intervention with juvenile sexual offenders. Family sometimes is a reason as to why juveniles offend. Some characteristics of the family of a juvenile sexual offender are troubled adolescent behavior, environment (can be either advantage or disadvantage neighborhoods, as in both good or both), and also has shown effects such as use of aggression and/or force. When a professional is deciding on a treatment for the adolescent they need to view the adolescent within